FDA warns of recalled compounded drugs in Michigan

The Food and Drug Administration is warning doctors, veterinarians and patients to avoid certain sterile drugs distributed by the Specialty Medicine Compounding Pharmacy of Michigan.

The pharmacy, in South Lyon near Detroit, has recalled drugs distributed in Michigan between July 1 and Oct. 19. The company says no drugs were distributed outside the state.

The specialty pharmacy agreed to conduct the recall after finding floating particles in a sterile that came from a lot that may have been given to hospital patients. The FDA says it's unclear what the particles were.

The FDA recommends doctors and stop using drugs from the pharmacy immediately. For additional details, the public can contact the Specialty Medicine Compounding Pharmacy at 248-446-2643.

No have been reported in connection with the recall.

Related Stories

FDA: Georgia pharmacy recalling all sterile drugs

date Mar 21, 2013

(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Indianapolis pharmacy recalls compounded drugs

date Apr 23, 2013

(AP)—A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.

Fla. compounding pharmacy recalls sterile drugs

date Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

US warns of mold in recalled specialty drugs

date Mar 18, 2013

The U.S. Food and Drug Administration warned doctors and hospital managers Monday about a nationwide recall of all drugs made by a New Jersey compounding pharmacy because of possible mold contamination.

Recommended for you

Teva buying Auspex for $3.2 billion

date 9 hours ago

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Oral hepatitis B vaccine could become a reality

date 11 hours ago

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.